litlas
Log inCreate account

Volker Diehl

Active 1967–2024

160
Papers
36,841
Citations
105
h-index
157
i10-index

Citations

Citations per year for Volker Diehl1967: 2 citations1968: 21 citations1969: 22 citations1970: 34 citations1971: 34 citations1972: 9 citations1973: 34 citations1974: 45 citations1975: 25 citations1976: 23 citations1977: 21 citations1978: 19 citations1979: 29 citations1980: 20 citations1981: 19 citations1982: 23 citations1983: 27 citations1984: 26 citations1985: 45 citations1986: 53 citations1987: 52 citations1988: 34 citations1989: 41 citations1990: 25 citations1991: 24 citations1992: 24 citations1993: 24 citations1994: 31 citations1995: 38 citations1996: 37 citations1997: 36 citations1998: 49 citations1999: 71 citations2000: 102 citations2001: 116 citations2002: 205 citations2003: 266 citations2004: 158 citations2005: 276 citations2006: 201 citations2007: 252 citations2008: 254 citations2009: 256 citations2010: 214 citations2011: 292 citations2012: 324 citations2013: 212 citations2014: 244 citations2015: 226 citations2016: 230 citations2017: 249 citations2018: 197 citations2019: 528 citations2020: 538 citations2021: 502 citations2022: 308 citations2023: 212 citations2024: 327 citations2025: 102 citations2026: 2 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,247 citing papers, 25.9% of this breakdownGermany: 950 citing papers, 11% of this breakdownUnited Kingdom: 586 citing papers, 6.8% of this breakdownItaly: 558 citing papers, 6.4% of this breakdownFrance: 516 citing papers, 6% of this breakdownCanada: 342 citing papers, 3.9% of this breakdownSwitzerland: 284 citing papers, 3.3% of this breakdownChina: 274 citing papers, 3.2% of this breakdownNetherlands: 273 citing papers, 3.1% of this breakdownSpain: 248 citing papers, 2.9% of this breakdownJapan: 210 citing papers, 2.4% of this breakdownAustralia: 208 citing papers, 2.4% of this breakdown
0%25.9%Other 22.7%

Institutions

Fields

  • Medicine83.6%
  • Immunology and Microbiology6.7%
  • Biochemistry, Genetics and Molecular Biology6.5%
  • Computer Science0.8%
  • Nursing0.7%
  • Physics and Astronomy0.2%
  • Other1.5%

Topics

  • Lymphoma Diagnosis and Treatment16.9%
  • Viral-associated cancers and disorders7.1%
  • CNS Lymphoma Diagnosis and Treatment4.5%
  • Chronic Lymphocytic Leukemia Research4.2%
  • CAR-T cell therapy research3.7%
  • Immune Cell Function and Interaction3.4%
  • Other60.2%

Coauthors

All papers

Open in search
  1. Revised Response Criteria for Malignant Lymphoma

    Authors: Bruce D. Cheson, Beate Pfistner, Malik E. Juweid, Randy D. Gascoyne, Lena Specht, Sandra J. Horning, Bertrand Coiffier, Richard I. Fisher, Anton Hagenbeek, Emanuele Zucca, Steven T. Rosen, Sigrid Stroobants, T. Andrew Lister, Richard T. Hoppe, Martin Dreyling, Kensei Tobinai, Julie M. Vose, Joseph M. Connors, Massimo Federico, Volker Diehl - Journal of Clinical Oncology 2007 cited by 4,448

  2. A Prognostic Score for Advanced Hodgkin's Disease

    Authors: Dirk Hasenclever, Volker Diehl, Jamés O. Armitage, David Assouline, Magnus Björkholm, Ercole Brusamolino, George P. Canellos, Patrice Carde, Derek Crowther, David Cunningham, Houchingue Eghbali, Christophe Ferm�, Richard I. Fisher, John H. Glick, Bengt Glimelius, Paolo G. Gobbi, Harald Holte, Sandra J. Horning, Tim Lister, Dan L. Longo, Franco Mandelli, Aaron Polliack, Stephen J. Proctor, Lena Specht, John Sweetenham, G. Vaughan Hudson - New England Journal of Medicine 1998 cited by 1,733

  3. Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma

    Authors: Andreas Engert, Annette Plütschow, Hans Theodor Eich, Andreas Lohri, Bernd Dörken, Peter Borchmann, Bernhard Berger, Richard Greil, Kay Willborn, Martin Wilhelm, Jürgen Debus, Michael J. Eble, Martin Sökler, Antony D. Ho, Andreas Rank, Arnold Ganser, Lorenz Trümper, Carsten Bokemeyer, Hartmut Kirchner, Jörg Schubert, Zdeněk Král, Michael Fuchs, Hans–Konrad Müller–Hermelink, Rolf‐Peter Müller, Volker Diehl - New England Journal of Medicine 2010 cited by 921

  4. Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial

    Authors: Peter Borchmann, Justin Ferdinandus, Gundolf Schneider, Alden A. Moccia, Richard Greil, Mark P. Hertzberg, Valdete Schaub, Andreas Hüttmann, Felix Keil, Judith Dierlamm, Mathias Hänel, Urban Novak, Julia Meißner, Andreas Zimmermann, Stephan Mathas, Josée M Zijlstra, Alexander Fosså, Andreas Viardot, Bernd Hertenstein, Sonja Martin, Pratyush Giri, Sebastian Scholl, Max S Topp, Wolfram Jung, Vladan Vučinić, Hans-Joachim Beck, Andrea Kerkhoff, Benjamin Unger, Andreas Rank, Roland Schroers, Christian Meyer zum Büschenfelde, Maike de Wit, Karolin Trautmann-Grill, Peter Kamper, Daniel Molin, Stefanie Kreissl, Helen Kaul, Bastian von Tresckow, Sven Borchmann, Karolin Behringer, Michael Fuchs, Andreas Rosenwald, Wolfram Klapper, Hans-Theodor Eich, Christian Baues, Athanasios Zomas, Michael Hallek, Markus Dietlein, Carsten Kobe, Volker Diehl - The Lancet 2024 cited by 114

  5. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial

    Authors: Norbert Schmitz, Beate Pfistner, M. Sextro, Markus Sieber, Angelo Michele Carella, Matthias W. Haenel, F. Boissevain, R. Zschaber, Peter E. Müller, Hartmut Kirchner, Andreas Lohri, Susanne Decker, Bettina Koch, Dirk Hasenclever, Anthony H. Goldstone, Volker Diehl - The Lancet 2002 cited by 1,132

  6. Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal Antibody (Rituximab, IDEC-C2B8)

    Authors: U. Winkler, Mark A. Jensen, Oliver Manzke, H. Schulz, Volker Diehl, Andreas Engert - Blood 1999 cited by 658

  7. PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group

    Authors: Peter Borchmann, Helen Goergen, Carsten Kobe, Andreas Lohri, Richard Greil, Dennis A. Eichenauer, Josée M. Zijlstra, Jana Marková, Julia Meißner, Michaela Feuring‐Buske, Andreas Hüttmann, Judith Dierlamm, Martin Soekler, Hans-Joachim Beck, Wolfgang Willenbacher, Wolf-Dieter Ludwig, Thomas Pabst, Max S. Topp, Felicitas Hitz, Martin Bentz, Ulrich Keller, Dagmar Kühnhardt, Helmut Ostermann, Norbert Schmitz, Bernd Hertenstein, Walter E. Aulitzky, Georg Maschmeyer, Tom Vieler, Hans Theodor Eich, Christian Baues, Harald Stein, Michael Fuchs, Georg Kuhnert, Volker Diehl, Markus Dietlein, Andreas Engert - The Lancet 2017 cited by 386

  8. Positron Emission Tomography–Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group

    Authors: Michael Fuchs, Helen Goergen, Carsten Kobe, Georg Kuhnert, Andreas Lohri, Richard Greil, Stephanie Sasse, Max S. Topp, Erhardt Schäfer, Bernd Hertenstein, Martin Soekler, Martin Vogelhuber, Josée M. Zijlstra, Ulrich Keller, Stefan W. Krause, Martin Wilhelm, Georg Maschmeyer, Julia Thiemer, Ulrich Dührsen, Julia Meißner, Andreas Viardot, Hans Theodor Eich, Christian Baues, Volker Diehl, Andreas Rosenwald, Bastian von Tresckow, Markus Dietlein, Peter Borchmann, Andreas Engert - Journal of Clinical Oncology 2019 cited by 229

  9. PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial

    Authors: Peter Borchmann, Annette Plütschow, Carsten Kobe, Richard Greil, Julia Meißner, Max S. Topp, Helmut Ostermann, Judith Dierlamm, Johannes Mohm, Julia Thiemer, Martin Sökler, Andrea Kerkhoff, Miriam Ahlborn, Teresa Halbsguth, Sonja Martin, Ulrich Keller, Stefan Balabanov, Thomas Pabst, Martin Vogelhuber, Andreas Hüttmann, Martin Wilhelm, Josée M. Zijlstra, Alden A. Moccia, Georg Kuhnert, Paul J. Bröckelmann, Bastian von Tresckow, Michael Fuchs, Beate Klimm, Andreas Rosenwald, Hans Theodor Eich, Christian Baues, Simone Marnitz, Michael Hallek, Volker Diehl, Markus Dietlein, Andreas Engert - The Lancet Oncology 2021 cited by 168

  10. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial

    Authors: Andreas Engert, Heinz Haverkamp, Carsten Kobe, Jana Marková, Christoph Renner, Antony D. Ho, Josée M. Zijlstra, Zdeněk Král, Michael Fuchs, Michael Hallek, Lothar Kanz, Hartmut Döhner, Bernd Dörken, Nicole Engel, Max S. Topp, Susanne Klutmann, Holger Amthauer, Andreas Bockisch, Regine Kluge, Clemens Kratochwil, Otmar Schober, Richard Greil, Reinhard Andreesen, Michael Kneba, Michael Pfreundschuh, Harald Stein, Hans Theodor Eich, Rolf‐Peter Müller, Markus Dietlein, Peter Borchmann, Volker Diehl - The Lancet 2012 cited by 632

  11. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial

    Authors: Karolin Behringer, Helen Goergen, Felicitas Hitz, Josée M. Zijlstra, Richard Greil, Jana Marková, Stephanie Sasse, Michael Fuchs, Max S. Topp, Martin Soekler, Stephan Mathas, Julia Meißner, Martin Wilhelm, P. Koch, Hans‐Walter Lindemann, Enrico Schalk, R. Semrau, Jan Kříž, Tom Vieler, Martin Bentz, Elisabeth Lange, Rolf Mahlberg, Andre Hassler, Martin Vogelhuber, D Hahn, J. Mezger, Stefan W. Krause, Nicole Skoetz, Boris Böll, Bastian von Tresckow, Volker Diehl, Michael Hallek, Peter Borchmann, Harald Stein, Hans Theodor Eich, Andreas Engert - The Lancet 2014 cited by 181

  12. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group

    Authors: Dennis A. Eichenauer, Annette Plütschow, Stefanie Kreissl, Martin Sökler, Johannes C. Hellmuth, Julia Meißner, Stephan Mathas, Max S. Topp, Karolin Behringer, Wolfgang Hiddemann, Georg Kuhnert, Markus Dietlein, Carsten Kobe, Michael Fuchs, Volker Diehl, Andreas Engert, Peter Borchmann - The Lancet Oncology 2017 cited by 113

  13. Cancer-Related Fatigue in Patients With and Survivors of Hodgkin Lymphoma: The Impact on Treatment Outcome and Social Reintegration

    Authors: Karolin Behringer, Helen Goergen, Horst Müller, Indra Thielen, Corinne Brillant, Stefanie Kreissl, Teresa Halbsguth, Julia Meißner, Richard Greil, Peter Moosmann, Oluwatoyin Shonukan, Jens Ulrich Rueffer, Hans‐Henning Flechtner, Michael Fuchs, Volker Diehl, Andreas Engert, Peter Borchmann - Journal of Clinical Oncology 2016 cited by 97

  14. Involved-Field Radiotherapy Is Equally Effective and Less Toxic Compared With Extended-Field Radiotherapy After Four Cycles of Chemotherapy in Patients With Early-Stage Unfavorable Hodgkin’s Lymphoma: Results of the HD8 Trial of the German Hodgkin’s Lymphoma Study Group

    Authors: Andreas Engert, Petra Schiller, Andreas Josting, Richard Herrmann, P. Koch, Markus Sieber, F. Boissevain, Maike de Wit, J. Mezger, E. Dühmke, Normann Willich, Rolf‐Peter Müller, Bernhard Schmidt, Helmut Renner, Hans Konrad Müller‐Hermelink, Beate Pfistner, Jürgen Wolf, Dirk Hasenclever, Markus Löffler, Volker Diehl - Journal of Clinical Oncology 2003 cited by 461

  15. PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial

    Authors: Stefanie Kreissl, Helen Goergen, Ina Buehnen, Carsten Kobe, Alden A. Moccia, Richard Greil, Dennis A. Eichenauer, Josée M. Zijlstra, Jana Marková, Julia Meißner, Michaela Feuring‐Buske, Martin Soekler, Hans-Joachim Beck, Wolfgang Willenbacher, Wolfgang Ludwig, Thomas Pabst, Max S. Topp, Felicitas Hitz, Martin Bentz, Ulrich Keller, Dagmar Kühnhardt, Helmut Ostermann, Bernd Hertenstein, Walter E. Aulitzky, Georg Maschmeyer, Tom Vieler, Hans Theodor Eich, Christian Baues, Harald Stein, Michael Fuchs, Volker Diehl, Markus Dietlein, Andreas Engert, Peter Borchmann - The Lancet Haematology 2021 cited by 68

  16. BRECADD IS NON‐INFERIOR TO EBEACOPP IN PATIENTS WITH ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA: EFFICACY RESULTS OF THE GHSG PHASE III HD21 TRIAL

    Authors: Peter Borchmann, Alden A. Moccia, Richard Greil, G Schneider, Mark Hertzberg, Valdete Schaub, Andreas Hüttmann, Felix Keil, Judith Dierlamm, Mathias Hänel, Urban Novak, Julia Meißner, Andreas Zimmermann, Stephan Mathas, Josée M. Zijlstra, Alexander Fosså, Andreas Viardot, Bernd Hertenstein, Sonja Martin, P. Giri, Peter Kamper, Daniel Molin, Stefanie Kreissl, Justin Ferdinandus, Michael Fuchs, Andreas Rosenwald, Wolfgang Hiddemann, Hans Theodor Eich, Christian Baues, Michael Hallek, Markus Dietlein, Carsten Kobe, Volker Diehl, Andreas Engert - Hematological Oncology 2023 cited by 24

  17. Relation of Burkitt's tumor-associated herpes-ytpe virus to infectious mononucleosis.

    Authors: Gertrude Henle, Werner Henle, Volker Diehl - National Academy of Sciences, Proceedings of the National Academy of Sciences 1968 cited by 1,214

  18. Artificial sweeteners—do they bear a carcinogenic risk?

    Authors: Martin R. Weihrauch, Volker Diehl - Annals of Oncology 2004 cited by 296

  19. Cancer-related fatigue in patients with and survivors of Hodgkin's lymphoma: a longitudinal study of the German Hodgkin Study Group

    Authors: Stefanie Kreissl, Horst Mueller, Helen Goergen, Axel Mayer, Corinne Brillant, Karolin Behringer, Teresa Halbsguth, Felicitas Hitz, Martin Soekler, Oluwatoyin Shonukan, Jens Ulrich Rueffer, Hans‐Henning Flechtner, Michael Fuchs, Volker Diehl, Andreas Engert, Peter Borchmann - The Lancet Oncology 2016 cited by 118

  20. Clonal Deleterious Mutations in the Iκbα Gene in the Malignant Cells in Hodgkin's Lymphoma

    Authors: Berit Jungnickel, Andrea Staratschek‐Jox, Andreas Bräuninger, Tilmann Spieker, Jürgen Wolf, Volker Diehl, Martin‐Leo Hansmann, Klaus Rajewsky, Ralf Küppers - The Journal of Experimental Medicine 2000 cited by 281

  21. Gonadal Function and Fertility in Survivors After Hodgkin Lymphoma Treatment Within the German Hodgkin Study Group HD13 to HD15 Trials

    Authors: Karolin Behringer, Horst Mueller, Helen Goergen, Indra Thielen, Angelika Diana Eibl, Volker Stumpf, Carsten Wessels, Martin Wiehlpütz, Johannes Rosenbrock, Teresa Halbsguth, Katrin S. Reiners, Thomas Schober, Jörg H. Renno, Michael von Wolff, Katrin van der Ven, Marietta Kuehr, Michael Fuchs, Volker Diehl, Andreas Engert, Peter Borchmann - Journal of Clinical Oncology 2012 cited by 261

  22. Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials

    Authors: Stephanie Sasse, Paul J. Bröckelmann, Helen Goergen, Annette Plütschow, Horst Müller, Stefanie Kreissl, Carolin Buerkle, Sven Borchmann, Michael Fuchs, Peter Borchmann, Volker Diehl, Andreas Engert - Journal of Clinical Oncology 2017 cited by 142

  23. Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin's Disease

    Authors: Volker Diehl, Jeremy Franklin, Michael Pfreundschuh, B. Lathan, Ursula Paulus, Dirk Hasenclever, Hans Tesch, Richard Herrmann, Bernd Dörken, Hans–Konrad Müller–Hermelink, E. Dühmke, Markus Loeffler - New England Journal of Medicine 2003 cited by 833

  24. Herpes-Type Virus and Chromosome Marker in Normal Leukocytes after Growth with Irradiated Burkitt Cells

    Authors: Werner Henle, Volker Diehl, Gertrude Kohn, Harald zur Hausen, Gertrude Henle - Science 1967 cited by 592